Coompo Research Chemicals

Astragaloside IV (AS-IV) is generally considered to be the primary active ingredient in Astragalus extract, an herbal extract which has been famous for literally thousands of years for its anti-aging properties.

AS-IV significantly reduced the adhesion promoting activity of LPS-stimulated HUVECs for polymorph-nuclear leukocytes (PMNs) and the monocytic cell line THP-1. Furthermore, by using specific cell ELISAs we could show that AS-IV decreased the LPS-induced expression of E-selectin and VCAM-1 on the surface of HUVECs in a dose and time dependent manner, whereas the expression of ICAM-1 was not affected by AS-IV. AS-IV also inhibits TNF alpha-induced VCAM-1 expression. The saponin octyl-D- glucopyranoside had no effect on the LPS-induced expression of E-selectin and VCAM-1 excluding an unspecific detergent-like effect of AS-IV. Moreover, AS-IV significantly inhibited LPS- and TNFalpha-induced specific mRNA levels for E-selectin and VCAM-1. Finally, we could show that AS-IV completely abolished LPS- and TNFalpha-induced nuclear translocation of NF-kappaB and NF-kappaB DNA binding activity in endothelial cells. We conclude that the ability of AS-IV to inhibit the NF-kappaB pathway might be one under-lying mechanism contributing to its anti-inflammatory potential in vivo.

AS-IV (1.0 mg/kg/day) attenuated the decrease of the left ventricle systolic pressure (LVSP). AS-IV treatment inhibited compensatory hypertrophy of myocardial cells and lowered the number of apoptotic myocytes. AS-IV improved cardiac functions as measured by cardiovascular parameters.
AS-IV, a novel antioxidant, to prevent Glucose-Induced podocyte apoptosis partly through restoring the balance of Bax and Bcl-2 expression and inhibiting caspase-3 activation.
AS-IV may be able to help protect telomeres and to prevent their deterioration over time due to stress and toxicity.

AS-IV to protect dopaminergic neurons (progressive degeneration of dopaminergic neurons leads to the development of Parkinson's disease).